$SWIM

MapLight Therapeutics (Nasdaq: MPLT) said it entered a securities purchase agreement for a private placement (PIPE) raising about US$150 million in gross proceeds, led by new and existing institutional investors. The deal is expected to close Aug. 14, 2026, subject to customary conditions. Latham & Watkins represents the placement agents.

Latham Group, Inc. (SWIM) reported Q2 2026 net sales of $197.5 million, up 14.4% year over year, driven by 10.3% organic growth and the Freedom Pools acquisition. Adjusted EBITDA rose to $44.6 million. Net income fell to $12.8 million due to a $5.0 million FX impact. Full-year guidance: net sales $600 million to $620 million, adjusted EBITDA $110 million to $120 million.

Innodata Inc. entered into a US$300 million at-the-market (ATM) offering on Aug. 6, 2026, according to the filing. Latham & Watkins LLP advised the placement agents, with additional counsel on data privacy and cybersecurity, intellectual property, and tax matters.

ICON plc (Nasdaq: ICLR) said its wholly owned subsidiary priced a US$2.15 billion senior unsecured notes offering. It includes US$500m 5.064% notes due 2029, US$1.0b 5.421% notes due 2031, and US$650m 5.995% notes due 2036. The offering is expected to close Aug. 13, 2026, subject to customary conditions.

BlossomHill Therapeutics priced an upsized US$150 million IPO, selling 9,375,000 shares at US$16.00 each, with gross proceeds expected to be US$150.0 million before fees. The underwriters received a 30-day option to buy up to 1,406,250 additional shares. Latham & Watkins advised the underwriters, with FDA and other specialty support.

Latigo Biotherapeutics priced an upsized US$345.6 million IPO, selling 19.2 million shares at US$18 per share. All shares were offered by Latigo, with gross proceeds expected to be US$345.6 million before fees. Underwriters have a 30-day option to buy up to 2.88 million additional shares at the same price. Latham & Watkins represented the underwriters.

Latham Group, Inc. reported Q2 2026 sales up 14% (10% organic) and raised full-year 2026 guidance, with sales growth midpoint to 11.7% and adjusted EBITDA midpoint to 15.2%. Management cited fiberglass share gains, marketing-driven demand, and Sand States growth. It expects to recover $2.8m ramp-up costs in H2 2026, target net debt leverage below 2.0, and noted $2.8m incremental margin pressure plus restructuring and earn-out charges.

Analysts cited bullish views on industrial and technology stocks. BTIG reiterated a Buy on V2X (VVX) with a $90 target versus a $78.76 close, and TipRanks consensus targets $89.30. Clear Street reiterated a Buy on Red Cat Holdings (RCAT) with a $19 target versus $8.86 close. Stifel reiterated Buy on Latham Group (SWIM) with a $9.50 target versus $5.70 close.

ContextLogic Holdings (OTCQB: LOGC) said it will acquire gChem, the holding company of Gaylord Chemical and subsidiaries, from funds managed by EagleTree Capital and co-investors. The deal values gChem at an enterprise value of US$850 million. Financing will come from Blackstone Credit & Insurance, including a US$250 million term loan and US$25 million revolver, per the company.

Latham (SWIM) shares rose about 27% after the company reported Q2 revenue of $197.5 million, up 14.4% year over year and above expectations, and raised full-year sales guidance to a $610 million midpoint. GAAP EPS and adjusted EBITDA fell short of forecasts. Shares closed at $7.29.